Australien - Englisch - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - valaciclovir hydrochloride monohydrate, quantity: 584 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; macrogol 8000; hypromellose; titanium dioxide; indigo carmine aluminium lake; stearic acid - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash. . for the treatment of ophthalmic zoster. . for the treatment of recurrent herpes labialis (cold sores) . for the treatment of clinical episodes of genital herpes simplex infections. . for the prevention of recurrent genital herpes in immunocompromised patients. . prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - valaciclovir hydrochloride monohydrate, quantity: 1168 mg - tablet, film coated - excipient ingredients: stearic acid; macrogol 8000; titanium dioxide; hypromellose; colloidal anhydrous silica - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash. . for the treatment of ophthalmic zoster. . for the treatment of recurrent herpes labialis (cold sores) . for the treatment of clinical episodes of genital herpes simplex infections. . for the prevention of recurrent genital herpes in immunocompromised patients. . prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - aciclovir, quantity: 800 mg - tablet - excipient ingredients: magnesium stearate; croscarmellose sodium; indigo carmine; microcrystalline cellulose; colloidal anhydrous silica; brilliant blue fcf - for use in adult patients for: 1. the treatment of first episode (primary or non-primary) genital herpes and the management of recurrent episodes of genital herpes in certain patients; 2. the treatment of acute attacks of herpes zoster (shingles), when the duration of rash is less than 72 hours; 3. the management of patients with advanced symptomatic hiv disease (cd4+counts, <150 x 10exp6/l). for use in accordance with details specified in the "indications" and the "dosage and adminsitration" sections of the approved product information document. a copy is provided as attachment 1.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - aciclovir -

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - valaciclovir hydrochloride monohydrate -

Irland - Englisch - HPRA (Health Products Regulatory Authority)

claris lifesciences (uk) limited - aciclovir - concentrate for soln for inf - 25 mg/ml - nucleosides and nucleotides excl. reverse transcriptase inhibitors

Irland - Englisch - HPRA (Health Products Regulatory Authority)

baxter holding b.v. - aciclovir - concentrate for solution for infusion - 25 milligram(s)/millilitre - nucleosides and nucleotides excl. reverse transcriptase inhibitors; aciclovir

Irland - Englisch - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - aciclovir sodium - concentrate for solution for infusion - 25 milligram(s)/millilitre - nucleosides and nucleotides excl. reverse transcriptase inhibitors; aciclovir

Irland - Englisch - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - aciclovir sodium; aciclovir sodium - concentrate for solution for infusion - 25 milligram(s)/millilitre - nucleosides and nucleotides excl. reverse transcriptase inhibitors; aciclovir

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - valaciclovir hydrochloride monohydrate -